Web4 mrt. 2024 · McDonagh TA, Metra M, Adamo M, et al. 2024 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2024;42:3599 … Web22 nov. 2024 · Eur J Heart Fail. 2024; 22:26–28. doi: 10.1002/ejhf.1689 Crossref Medline Google Scholar; 14. Vergaro G, Ghionzoli N, Innocenti L, Taddei C, Giannoni A, Valleggi …
Frontiers Phenotypic patient profiling for improved …
Web27 aug. 2024 · Acute Heart Failure Sophia Antipolis, France – 27 Aug 2024: The European Society of Cardiology (ESC) Guidelines for the diagnosis and treatment of acute and … Web5 apr. 2024 · Vericiguat is a new medication therapy choice for the patients with heart failure with reduced ejection fraction (HFrEF), in the latest trial, it met the expectation to reduce incidence of death from cardiovascular causes or hospitalization for heart failure among HFrEF patients. charlbury to oxford
2024 ESC Guidelines for the Diagnosis and Treatment of Acute …
Web28 jan. 2024 · McDonagh TA, Metra M, Adamo M, et al. 2024 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J … Web17 jan. 2024 · Eur Heart J 2016; 37(27): 2129–2200. 2. McDonagh TA, Metra M, Adamo M, et al. 2024 ESC Guidelines for the diagnosis and treatment of acute and chronic heart … Web12 apr. 2024 · Background: Data on the impact of sacubitril/valsartan (SV) therapy on phasic left atrial (LA) and left ventricular (LV) strain in heart failure with reduced ejection fraction (HFrEF) are limited. The aim of this study was to evaluate changes in two-dimensional speckle tracking (2D-STE) parameters with SV therapy in HFrEF patients. Methods: … charlbury to witney